Reference number : 276-2020-2021-Q2-00422, amendment number : , agreement type : C, recipient legal name : Immunovaccine Technologies Inc.|Immunovaccine Technologies Inc., recipient country : CA, recipient province : NS, recipient city : Dartmouth|Dartmouth, recipient postal code : B3B 2C4, program name english : REGI - Business Scale-up and Productivity, program name french : CERI - Expansion et productivité des entreprises, program purpose english : nan, program purpose french : nan, agreement title english : 215122, agreement title french : 215122, agreement number : 215122, agreement value : 1000000.0, agreement start date : 2020-09-17, agreement end date : 2020-12-31, description english : Support pre-clinical development activities for COVID-19 vaccine, description french : Support pre-clinical development activities for COVID-19 vaccine, expected results english : nan, expected results french : nan, additional information english : The assistance type is Conditionally Repayable Contribution. The total government funding is $1,383,000.00., additional information french : Le type d'aide est contribution à remboursement conditionnel. Le financement gouvernemental total est 1 383 000,00 $., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique